## Chronic Lymphocytic Leukemia (CLL) in Elderly Patients **Key Point:** Chronic lymphocytic leukemia is the most common chronic leukemia in elderly patients (>60 years) in Western populations and is increasingly recognized in India. It is a B-cell malignancy characterized by progressive accumulation of functionally incompetent lymphocytes. ### Clinical and Immunophenotypic Features of CLL | Feature | CLL | |---------|-----| | **Median age at diagnosis** | 70–72 years | | **Male:Female ratio** | 2:1 | | **Presentation** | Often asymptomatic (30–50% discovered incidentally) | | **Lymphocytosis** | >5,000/μL lymphocytes (often >10,000/μL) | | **Lymphadenopathy** | Present in 50–80% of cases | | **Splenomegaly** | Present in 25–50% of cases | | **Flow cytometry** | CD5+, CD19+, CD23+, CD10−, FMC7− (co-expression of T-cell and B-cell markers) | | **Bone marrow** | Lymphocytic infiltration (interstitial or diffuse) | ### Immunophenotypic Distinction: CLL vs. Other B-Cell Lymphomas | Marker | CLL | Lymphoplasmacytic | Marginal Zone | |--------|-----|-------------------|---------------| | **CD5** | + | − | − | | **CD19** | + | + | + | | **CD23** | + | − | − | | **CD10** | − | − | − | | **Surface Ig** | Weak | Strong | Weak | | **Monoclonal protein** | Rare | Common (IgM) | Rare | **High-Yield:** The CD5+, CD19+, CD23+ immunophenotype is pathognomonic for CLL. CD5 is a T-cell marker aberrantly expressed on B cells in CLL, which is a key diagnostic feature. The combination of CD5 and CD23 co-expression distinguishes CLL from other B-cell malignancies. **Clinical Pearl:** In elderly Indian patients, CLL may present late with advanced-stage disease due to delayed diagnosis. Rai and Binet staging systems are used to stratify prognosis and guide treatment decisions. Early-stage asymptomatic CLL may be managed with "watch and wait" strategy, while symptomatic or advanced-stage disease requires chemotherapy or targeted therapy (BTK inhibitors, BCL2 inhibitors). **Mnemonic: CLL = CD5 + CD19 + CD23 = Classic Chronic Lymphoid Leukemia** — the triple marker combination is the immunophenotypic hallmark.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.